Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
Shio-Shin JeanCarlos Lam

Abstract

To compare the clinical efficacy between salvage antimicrobial regimen consisting of tigecycline plus extended-infusion imipenem/cilastatin (TIC) and regimen of sulbactam plus imipenem/cilastatin (SIC) for patients with ventilator-associated pneumonia and pneumonic bacteremia due to extensively drug-resistant (XDR) Acinetobacter baumannii (Ab) isolates, and determine the correlation of results of in vitro tigecycline-imipenem synergy test with clinical efficacy. The comparative survey was conducted at a medical center in Taiwan in 2013. Patients comprising the TIC group (n = 28) received tigecycline plus extended-infusion imipenem/cilastatin following unresponsiveness to 3-day sulbactam-imipenem/cilastatin therapy, and those in the SIC group (n = 56) received sulbactam-imipenem/cilastatin throughout the course. Univariate and multivariate analyses were applied to explore 30-day case-fatality independent predictors. Additionally, the checkerboard test and time-kill analysis were performed for the bloodstream XDR-Ab isolates from patients in the TIC group, and molecular characterization was done for the bloodstream XDR-Ab strains of all patients. We found that the TIC scheme has a significant benefit on improving patients' surviv...Continue Reading

References

May 25, 1994·JAMA : the Journal of the American Medical Association·D PittetR P Wenzel
Mar 13, 1999·International Journal of Antimicrobial Agents·J W Chow, V L Yu
Jan 20, 2004·The Journal of Antimicrobial Chemotherapy·Wen-Chien KoYin-Ching Chuang
Feb 9, 2005·American Journal of Respiratory and Critical Care Medicine·UNKNOWN American Thoracic Society, UNKNOWN Infectious Diseases Society of America
Apr 26, 2005·Scandinavian Journal of Infectious Diseases·Chun-Ming LeeHsiang-Kuang Tseng
Jul 29, 2005·Antimicrobial Agents and Chemotherapy·Claire HéritierPatrice Nordmann
Nov 10, 2006·Journal of Clinical Microbiology·Ronald N JonesHelio S Sader
May 10, 2007·Drugs·George G ZhanelJames A Karlowsky
Feb 25, 2009·Critical Care Medicine·Jason A Roberts, Jeffrey Lipman
Mar 13, 2009·International Journal of Antimicrobial Agents·Olaf BurkhardtTobias Welte
Jul 6, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul G AmbroseGeorge L Drusano
Aug 18, 2010·Antimicrobial Agents and Chemotherapy·Madhuri M SopiralaPreeti Pancholi
Sep 18, 2010·Diagnostic Microbiology and Infectious Disease·Antonio T FreireUNKNOWN 311 Study Group
Jan 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yu-Chung ChuangShan-Chwen Chang
Feb 9, 2011·Antimicrobial Agents and Chemotherapy·T P LodiseG L Drusano
Apr 29, 2011·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Li-Yuan ChenPo-Liang Lu
May 18, 2011·Antimicrobial Agents and Chemotherapy·G L DrusanoA Louie
Sep 8, 2011·Expert Opinion on Pharmacotherapy·Shio-Shin Jean, Po-Ren Hsueh
Apr 5, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Y-T LeeP-R Hsueh
Jun 4, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yu-Chung ChuangShan-Chwen Chang
Sep 26, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Wen-Wei KuChang-Phone Fung

❮ Previous
Next ❯

Citations

Jan 23, 2020·Journal of Clinical Medicine·Shio-Shin JeanChin-Wan Hsu
Apr 7, 2017·Annals of Clinical Microbiology and Antimicrobials·Jian WangYuanhong Xu
Aug 28, 2021·Infection and Drug Resistance·Nancy G BanoubKhaled M Aboshanab

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.